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Summary
 Background Data on epidemiology and survival after fungal infections in patients with cancer 
are primarily based on studies in adults, whereas few data are available on chil-
dren.
 Aim The objective of this study was to determine the safety and tolerability of the 
oral and i.v. formulations of voriconazole Vfend®, previously not reported in 
Poland.
 Materials/Methods Twenty consecutive children and young adults aged 1 to 25 years, submitted for 
blood and marrow transplantation (BMT), were recruited during 10 months. 
When suspected or veriﬁ ed breakthrough systemic fungal infection occurred 
while kept on primary prophylactic ﬂ uconazole regimen, all patients received 
two loading doses of i.v. or oral voriconazole 6–9 mg/kg every 12 hrs, followed 
by a maintenance dose of 3 mg/kg every 12 hrs for ﬁ ve doses. If well tolerated, 
the voriconazole dosage was increased to 4 mg/kg every 12 hrs thereafter.
 Results Fungal infection was possible in 15/20, organ involvement with pulmonary proc-
ess in 13 pts; CNS changes in 2 pts. Fungal aetiology was proven in 3 children (pul-
monary Aspergillosis in 2 and Candida krusei in 1 patient), and considered as 
probable in 2 patients, having lung (2) and CNS (1) involvement. Four patients 
died. Clinical and radiological improvement was obtained in 14 patients, while 
uncontrolled, progressive disease occurred in 1 patient. Transient visual distur-
bances occurred in one patient. Major caution is warranted due to drug interac-
tion via the cytochrome P-450 system which may lead to unexpected toxicity of 
the coadministered drugs (e.g. Vinca alkaloids, cyclosporine, rifampicin, eryth-
romycin, etc).
 Conclusions Voriconazole is an advantageous new azole well tolerated in 20 patients. Outcome 
in BMT breakthrough infections was good.
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BACKGROUND
Systemic (invasive) infections termed ‘mycoses’ 
are often fatal or life-threatening conditions in 
immunocompromised patients [1]. Some fungal 
infections only (for example, histoplasmosis, blas-
tomycosis and coccidioidomycosis) can be seri-
ous in otherwise healthy people. Certain types of 
fungi (such as Candida) are normally present on 
body surfaces or in the intestines. Although nor-
mally harmless, these fungi sometimes cause lo-
cal infections of the skin and nails, vagina, mouth 
or sinuses. They seldom cause serious harm, ex-
cept in people with a weakened immune system 
or with foreign material (such as an intravenous 
catheter) in their body. These are for example 
individuals who have received an organ trans-
plant, are being treated for cancer with immu-
nosuppressive drugs, or who have AIDS.
Of the wide variety of spores that land on the 
skin or are inhaled into the lungs, most do not 
cause infection. The normally present bacterial 
ﬂ ora in the digestive tract and vagina limit the 
overgrowth of certain fungi. When a person takes 
antibiotics, those helpful bacteria can be killed 
– allowing overgrowth of the fungi, resulting in 
symptoms which are usually mild. As the normal 
ﬂ ora grows back, the balance is restored, and the 
problem usually resolved [2]. Data on epidemi-
ology and survival after fungal infections in pa-
tients with cancer are primarily based on studies 
in adults, whereas few data are available on chil-
dren where the overall and the infection-specif-
ic (fungemia or mycosis with deep tissue infec-
tion) mortalities are lower [3,4].
AIM
The objective of this study was to determine the 
safety and tolerability of the oral and i.v. for-
mulations of voriconazole Vfend® in clinical 
prophylactic and therapeutic setting in blood 
and marrow transplanted (BMT) children and 
young adults. Its use has not yet been reported 
in Poland.
MATERIALS AND METHODS
Twenty consecutive immunocompromised chil-
dren and young adults aged 1 to 25 years with 
non-malignant and malignant diseases submit-
ted for BMT were included in the study during 
10 months’ observation, 01.01.2006–30.09.2006 
(Tables 1 and 2). All 20 patients enrolled were 
expected to develop neutropenia lasting for >10 
days following the preparative regimen for BMT. 
EORTC criteria were used for classifying fungal 
infection as possible, proven or probable [5].
Study design
When a patient developed signs and symptoms 
of breakthrough systemic (suspected or veri-
ﬁ ed) fungal infection while kept on ﬂ uconazole 
prophylaxis, the drug was stopped and the patient 
switched over to voriconazole and enrolled in the 
study. All patients received two loading doses of 
i.v. or oral voriconazole 6–9 mg/kg every 12 hrs, 
followed by a maintenance dose of 3 mg/kg eve-
ry 12 hrs for ﬁ ve doses. If the 3-mg/kg dosage was 
well tolerated, the dosage was increased in that 
patient to 4 mg/kg every 12 hrs thereafter. The 
patients were permitted to continue in the study 
until day 7–50 if clinically indicated. No other 
antifungals were used in patients while on vori-
conazole therapy. The parents or legally author-
ized representative of underage patients as well 
as patients capable of understanding the study 
(aged 18 yrs and above) consented to the study 
before enrolment.
RESULTS
Fungal infection was judged possible in 15/20 pa-
tients. Organ involvement with pulmonary proc-
ess was present in 13 pts, CNS changes in 2 pts. 
Fungal aetiology was proven in 3 children hav-
ing pulmonary process. Aspergillus aetiology was 
eventually ruled out in 2 pts and Candida kru-
sei in 1 patient. Fungal infection was in addition 
considered as probable in 2 patients, having lung 
(2) and CNS (1) involvement.
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Four patients eventually died of infection com-
plicated with multi-organ failure. Clinical and ra-
diological improvement was obtained in 14 pa-
tients, while uncontrolled, progressive disease 
occurred in 1 patient. One patient still has on-
going VCZ treatment.
Adverse effects
Transient visual disturbances occurred in one pa-
tient. As for caring for complicated clinical prob-
lems and giving advanced supportive treatment, 
a lot of difﬁ cult problems were present. It was the 
investigators’ decision to determine whether the 
problem was induced by concomitant infections 
(bacterial septicaemia, viral reactivation) and/or 
subsequent polypragmasia using a lot of i.v. med-
ications. Monitoring the patients by routine kid-
ney and liver function test, there were no overt 
adverse events.
Safety assessments and criteria
Physical examinations and routine clinical labo-
ratory tests were conducted at baseline and twice 
weekly, including the last day of administration 
of the study drug. As voriconazole is known to be 
associated with transient visual changes, patients 
having ocular problems were assessed for visual 
symptoms during therapy. If the patients were able 
and willing to cooperate, the following tests were 
performed by an ophthalmologist on clinical de-
mand: near visual acuity in each eye, obtained us-
ing Snellen letters; and dilated fundoscopic ex-
amination with indirect ophthalmoscopy, paying 
particular attention to the optic nerves, retinal 
vessels, macula, retina and choroid vessels.
DISCUSSION
This study is to our knowledge the ﬁ rst systematic 
investigation of the safety and tolerability of the 
parenteral and oral formulation of voriconazole 
following breakthrough fungal infection in im-
munocompromised paediatric patients kept on 
ﬂ uconazole prophylaxis in Poland. The patients 
enrolled in this study were immunocompromised 
children who were at risk for development of inva-
sive fungal infections. The dosages administered 
in this trial were those that have been found to 
be effective in clinical trials in adults. The dosage 
range was selected to explore the same dosage 
that is used in adults. Safety was an overarching 
concern in designing this paediatric study, partic-
ularly given previous data in adults demonstrat-
ing nonlinear kinetics and potentially marked in-
creases in plasma drug concentrations between 
the dosages of 3 and 4mg/kg. Voriconazole was 
well tolerated but was associated with transient 
visual disturbances in one patient.
Voriconazole is a newer antifungal agent belong-
ing to the triazole class, generally better tolerat-
ed, having a broad spectrum. Available for oral 
use with almost complete absorption, it is suita-
ble for use in paediatric patients both as an oral 
preparation and for intravenous infusion. Having 
an extensive hepatic metabolism, approximate-
ly 80% of a single dose appears in the urine, but 
less than 5% is excreted in its unchanged form. 
Widely distributed in body tissues and ﬂ uids, it 
has an advantage penetrating into the brain and 
CSF. Unwanted effects include mild to moderate 
visual disturbances, skin rashes and transient ab-
normalities of liver enzymes [6,7]. The azoles are 
generally fungistatic (especially in Candida) and 
resistance to ﬂ uconazole is emerging in several 
fungal pathogens. All the azoles inhibit the P450 
Patients 20
Age 1–25 years
Sex: F: M 1: 19
Kind of transplant 18 MUD, 2 Haplo, 1 MSD
Table 1. Summary of the patient material and BMT procedure.
MUD–matched unrelated donor; Haplo – haploidentical;
MSD – matched sibling donor.
Conditions – diseases Number of patients
Severe Aplastic Anaemia 1
Omenn Syndrome 1
Severe Combined Immune Defi ciency 1
Non-Hodgkin’s Lymphoma 1
Fanconi Anaemia 1
Chronic Granulomatous Disease 1
Acute Lymphoblastic Leukaemia 6
Acute Myeloid Leukaemia 1
Juvenile Myelo-Monocytic Leukaemia 1
Chronic Myeloid/Granulocytic Leukaemia 4
Myelodysplastic Syndrome 2
Table 2. BMT performed for non-malignant and malignant 
diseases.
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enzymes responsible for the synthesis of ergoster-
ol, the main sterol in the fungal cell membrane. 
A major concern is that azole-drug interaction 
may lead to unexpected toxicity of the coadmin-
istered drug (e.g. Vinca alkaloids, cyclosporine, 
rifampicin, erythromycin, etc) relating to the 
ability of the azoles to increase plasma concen-
trations of other drugs by altering hepatic metab-
olism via the cytochrome P-450 system.
As azole antifungal agents have become important 
in the treatment of mucosal candidiasis in AIDS 
patients, reports of resistance have increased. In 
fact, azole resistance has now been found in pa-
tients not infected with HIV and, in some situa-
tions, in patients not previously exposed to anti-
fungal agents [8,9].
In common with all azole antifungal agents, ﬂ u-
conazole may cause hepatotoxicity.
Serious superﬁ cial infections are relatively uncom-
mon. During the last 3–4 decades there has been 
a steady increase in the incidence of serious sys-
temic/invasive fungal infections. One factor has 
been the widespread use of broad-spectrum anti-
biotics, which eliminate or decrease the non-path-
ogenic bacterial populations that normally com-
pete with fungi. Another has been the increase 
in the number of individuals with reduced im-
mune responses due to AIDS or the action of im-
munosuppressant drugs or cancer chemothera-
py agents; this has led to increased prevalence of 
opportunistic infections, i.e. infections with fungi 
which are either innocuous or readily overcome 
in immunocompetent individuals.
Data on epidemiology and survival after fungal 
infections in patients with cancer are primarily 
based on studies in adults, whereas few data are 
available on children. Risk factors are considered 
to be prolonged neutropenia, congenital granu-
locyte function deﬁ cits (chronic granulocytope-
nia) and defective T-cell immune response.
CONCLUSIONS
•  Voriconazole is an advantageous new azole well 
tolerated in 20 patients.
•  Transient visual disturbance occurred in one 
case only.
•  Numerous drug interactions were document-
ed, warranting drug interaction.
•  Outcome in BMT breakthrough infections was 
good. Risk factors were prolonged neutrope-
nia, GvHD, previous history of risk factors and 
drug interaction.
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